Frontlight ResearchEarly access
WithdrawnPhase 4
Suprascapular Nerve Block for Treatment of Shoulder Pain in Individuals With Spinal Cord Injuries
Key facts
- Who runs it
- University of Miami
- Where
- Miami, United StatesSee the site
- Trial code
- Status
- Withdrawn
- Phase
- Phase 4
- Started
- 27 Nov 2023
- Ended
- 1 Jan 2024
- Type of study
- Interventional
- Treatments tested
- Lidocaine 1% Injectable Solution
- Triamcinolone Injection
- Suprascapular Nerve Block
- Record updated
- 6 December 2023
- Why it stopped
- Unable to feasibly complete study.
Who can take part
- Age
- 18 years to 70 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Male or female, 18-70 years of age, inclusive. 2 Neurological impairment secondary to SCI that occurred at least twelve (12) months prior to the Screening Visit; neurological level of injury between C6 and L5, inclusive
- Non-ambulatory, except for exercise or therapy purposes. 4. Uses a manual wheelchair. 5 History of chronic shoulder pain for ≥6 months that has been unresponsive to conservative treatment (e.g. physical therapy, pharmacological agents), and is rated as ≥4 out of 10 on an 11-point Numeric Rating Scale (NRS) (0 = "no pain"; 10 = "most intense pain imaginable") for average shoulder pain intensity during the week leading up to the Screening Visit
- Able and willing to comply with the protocol. 7. Able to give voluntary informed consent prior to the performance of any study-specific procedures
Who cannot take part
- Prior history of regenerative medicine intervention
- Contra-indications to the procedure (e.g. infection, coagulopathy)
- History of active cancer within 5 years
- Any medical condition, including psychiatric illness, which would interfere with the interpretation of the study results or the conduct of the study
- Adhesive capsulitis
- Glucocorticoid injection within the past four weeks
Where in United States
- University of MiamiMiami, United States
About the trial
What the trial wants to find out
The purpose of this study is to evaluate the effectiveness and safety of using suprascapular nerve block for individuals with chronic spinal cord injury who have chronic shoulder pain.
The group in the trial
- Suprascapular Nerve Block in Participants with Spinal Cord Injuries (SCI) GroupTreatment being tested
Participants in this group will receive standard of care (SOC) suprascapular nerve block using a mixture of Lidocaine and Triamcinolone.
Treatment: Lidocaine 1% Injectable Solution, Triamcinolone Injection, and Suprascapular Nerve Block
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 6 December 2023